SF3B1 and myelodysplastic syndrome: Patients with ASXL1, TET2, STAG2, RUNX1, SF3B1, SRSF2, DNMT3A, U2AF1, and BCOR mutations or patients classified as MDS, NOS with SLD/MLD based on the 2022 ICC, complementary genetic analyses including KMT2A-PTD were recommended for accurate IPSS-M classification, which would lead to different treatments strategies in a significant proportion (>5%) of the patients.